L-2,5-Dihydrophenylalanine is extensively incorporated as a phenylalanine analogue into cell proteins. Phenylalanine-requiring Escherichia coli ATCC 9723f and sarcoma 180 grow at normal rates initially with the analogue and maximally replace 65 and 33%, respectively, of phenylalanine in the peptide residues of their cell protein without death. With the analogue alone growth of E. coli becomes non-steady-state and asymptotically inhibited. In mixtures of the analogue and phenylalanine, growth eventually becomes steady state or logarithmic. The logarithmic rate is inversely proportional to the extent of incorporation of this analogue or of p-fluorophenylalanine, and the projected maximal replacement is the same as that obtained asymptotically with the analogue alone. Thus, the toxicities in steady-state and non-steady-state growth are closely related. Moreover, it is proposed that single salient protein defects may determine the extent of growth rate reduction.
L-2,5-Dihydrophenylalanine (pheH2) was reported first as a product of the Birch reduction of phenylalanine (phe) (10) and subsequently as an antibiotic synthesized by streptomyces (2, 8, 11) . It is a growth antagonist of phe in microbes and the rat (3, 5, 10) . In Escherichia coli it represses synthesis of the initial enzyme of aromatic biosynthesis, a function attributed to phe-transfer ribonucleic acid (3) . The possibility that pheH2 may ligate to transfer ribonucleic acid and thus incorporate into cell protein is now bome out in E. coli and sarcoma 180 (S-180). Further, steady-state and asymptotic growth responses to pheH, administration have been compared. Steady-state or logarithmic growth of phe-requiring E. coli could be maintained with balanced mixtures of phe and pheH,, enriching the cell proteins randomly and equally with analogue. Administration of pheH2 alone in contrast induces steadily decreasing or asymptotic growth, with separate populations of normal and pheH2-substituted cell proteins. A simple relationship could be established between these two methods for the administration of pheH2 and perhaps other phe analogues in E. coli. With analogues of additional amino acids and with other growth systems, however, the relationship may be more complex.
MATERIALS AND METHODS
A derivative of E. coli ATCC 9723f requiring phe, proline, methionine, and arginine was routinely cultivated in a minimal medium of salts, glucose, and required amino acids, as previously described (7).
Tyrosine was also added at 10 lg/ml to eliminate the side effects of phe analogue on tyrosine metabolism (3, 4, 5 ). An inoculum in early growth (7) was washed on a cellulose membrane filter in phe-deficient medium, and 2 x 106 cells per ml was supplemented with phe and its analogues. Growth rates were estimated turbidimetrically (7) over a time period that would comprise 5 to 7.5 cell generations after inoculation. When analogue was substituted totally for phe, higher inocula were used and incubated overnight after growth had become stationary at mid-growth turbidities. For amino acid analyses the cells were boiled for 30 min in 0.1 N HCIO4, washed in 10% trichloroacetic acid, acetone, and then chloroformmethanol (2:1). Cell protein was hydrolyzed at 100 C overnight in vacuo, either in 6 N HCl for recovery of oor p-fluorophenylalanine, or in 3 N KOH for recovery of pheH2. Ratios of phe and its analogues in the hydrolysate and in various preparations were determined with a Beckman model 121 amino acid analyzer (1) . For o-fluorophenylalanine analysis, the interfering peak of tyrosine was removed from the hydrolysate in 0.05 M tris(hydroxymethyl)aminomethane, pH 8.0, for 1 h at room temperature with C(N02)4 at 3% of the final volume, followed by removal of the reagent with ether and reacidification. Corrections were made for destruction of 14% of supplied pheH2 and conversion of 2% to phe during alkaline hydrolysis, and for phe contamination of 11 gAg/ml in 5% dialyzed horse serum and of 3 to 7% in different preparations of pheH2.
To observe growth of S-180 cells, an inoculum of 5 X 104 cells was grown in stoppered test tubes (12 by 75 mm) for 4 days in two changes of 2 ml of minimal 601 ANTIMICROB. AGENTS CHEMOTHER.
Eagle medium with Hanks salts and 5% horse serum. Growth was determined by protein analysis (6) of the centrifuged washed cells. For incorporation of radiolabeled amino acid, the cells of confluent cultures were trypsinized, washed in the base of salts and glucose, and concentrated twofold in the Eagle medium without phe or valine.and with 10% horse serum that had been dialyzed against saline for 3 h. One milliliter of the cell suspension was supplemented with uniformly labeled [3H]phe at varying concentrations plus 0.4 mM uniformly labeled [14C0valine, each at 0.32 mCi/mmol. After 2 h of incubation under air plus 5% CO2 at 37 C in a Dubnoff shaker, the suspensions were diluted with excess medium, chilled, filtered on cellulose acetate membranes with saline followed by 10% trichloroacetic acid, dried at 60 C, combusted in growth leveled off slowly and stopped after several hours, as judged either turbidimetrically or by colony counts on nutrient agar. Thus the viable cell number tripled and remained constant for 6 h. After 16 h, pheH2 was found to replace 65% of the cell peptide phe. This represents the limit of incorporation at zero growth rate under conditions of non-steady-state growth. In terms of cell turbidity increase ( Fig.  1) , growth in pheH2 is nonlogarithmic and becomes self-limiting. If the growth curve is plotted linearly, it still appears slightly convex rather than strictly linear and then presumable breaks and approaches an asymptotic limit. In contrast, at varying ratios of phe and pheH2, a range of steady-state or logarithmic growth rates was obtained (Fig. 1) . As many as four cell generations elapsed before growth attained these rates, judging from the time of appearance of minimal turbidity. An inverse linear correlation appears between the steady-state growth rates and the extent to which pheH2 replaces peptide phe in cell protein (Fig. 2) . Moreover, the line extrapolates to the non-steady-state limit of phe replacement at the ordinate. Thus the interpretation is made that toxicity during non-steady-state administration is basically no different from steady-state toxicity, and that 10 TIME I ' Ih I during non-steady-state toxicity growth slows down to an extent predictable from intermediate steady-state levels of incorporation until the growth eventually ceases.
pheH2 was a more effective antagonist of phe than DL-0-or p-fluorophenylalanine. A threefold greater L-analogue-phe ratio of 30:1 was required for 50% growth inhibition when the latter analogues were supplied at 0.2 mM (as the L form). These and additional steady-state growth rates obtained by varying the phe level show varying linearity when plotted versus replacement of peptide phe, and the analogues resemble pheH2 closely in their maximal or limiting replacement of peptide phe (Fig. 2) . However, the relationship between partial peptide replacement by o-fluorophenylalanine and growth rate may more properly be described by a convex line (Fig. 2) . Additional studies were made of L-norleucine as a substitute for methionine and of DL-3,4-dehydroproline and L-azetidine-2-carboxylate as substitutes for proline. The depressed growth rates in methionine antagonism appeared steady. In proline antagonism, however, growth tended either to recover to normal after a lag or to become increasingly depressed and to level off. Thus the antagonism between certain amino acids and their analogue may not lend itself to the present analytical approach.
Effects of pheH2 incorporation on S-180 cells. During a comparatively short exposure of 2 h in pheH2-phe mixtures, growth as judged from ["4C]valine incorporation remains at least at 75 to 80% of normal at the highest ratios, while incorporation of [3H ]phe is selectively depressed as much as 88% (Fig. 3) . pheH2 evidently can almost totally substitute for phe initially at nearly normal growth rates. Replacement of phe, selected at 45% of the maximum [3H]phe incorporation, occurs at virtually the same pheH2-phe ratio, 2.0:1, 2.2:1 and 2.3:1, at 0.03, 0.09 and 0.3 mM phe concentrations, respectively. pheH2 is therefore competitive with phe over a 10-fold concentration range which is adequate for maximum growth.
Exposure to pheH2-phe mixtures for 4 days gives complex growth kinetics. The reciprocals of growth rate versus phe concentration are plotted in Fig. 4 . At comparatively low VOL. 7, 1975 on pheH2-phe ratios the curves are linear and tend to converge at the ordinate, suggesting competitive interaction between pheH2 and phe expressed by balanced changes in growth rate. Thus the pheH2-phe ratios for 50% inhibition of growth are fairly constant at 0.23, 0.19, and 0.18 at 0.03, 0.1, and 0.3 mM phe, respectively. At higher pheH2-phe ratios, growth is not proportionately suppressed. As corroborated by the leveling of the curves, cell protein still increases by a minimum of 50%, reflecting unbalanced incorporation of pheH2 until zero growth rate is reached. When 0.3 mM pheH2 was substituted completely for phe in S-180 cells at one-third confluence, they became rounded and ready to detach from the flask surface after 24 h. pheH2 had replaced 33% of the peptide phe, in accordance with the 50% increase in protein just noted. The cells were still viable as judged by exclusion of trypan blue and by resumption of normal morphology and reinitiation of growth when phe was restored. In a mixture of 0.3 mM phe and 0.06 mM pheH2, which would give a half-maximal growth rate, pheH2 replaced 7% of peptide phe after a 10-fold cell increase and 5% after a repeated subculture. These peptide replacement levels are decidely less than half the maximum of 33% replacement obtained with incorporation of pure pheH2. Thus, cell biosynthesis in S-180 is more susceptible to steadystate than to non-steady-state administration of pheH2. DISCUSSION pheH2 replaces phe virtually completely at normal or nearly normal growth rates in E. coli phe and S-180 cells. E. coli growth increased maximally threefold, as evidenced by a threefold increase in viable cell number and replacement of two-thirds of protein phe. Upon the latter criterion, pheH2 resembles o-and pfluorophenylalanine, and would thus appear exemplary of those amino acid analogues that approximate the molecular structure of the parent molecule sufficiently to duplicate it adequately at almost all peptide sites where it has a more than neutral role (4) . In contrast, incorporation of a less accommodating amino acid analogue such as canavanine produces a comparatively abrupt cessation of protein biosynthesis and rapid lethality (9) . The combined affinity of pheH2 for cellular uptake and ligation to transfer ribonucleic acid is still high, at about half that of phe, in S-180. This is concluded from the 50% replacement of peptide phe after 2 h of incorporation at a 2:1 pheH2-phe ratio, and 5% replacement after a 100-fold increase in cell number at a 0.2:1 pheH2-phe ratio. In E. coli the corresponding pheH2-phe ratio for 50% growth inhibition is 10:1. A low steady-state growth rate can still be maintained in E. coli when pheH2 has replaced nearly half of the peptide phe of the cell. In this respect pheH2 is not notably different from o-and p-fluorophenylalanine. Extensive analogue re-INCORPORATION OF L-2,5-DIHYDROPHENYLALANINE 605 placement of phe must give rise to a variety of biochemical defects. However, the high capacity for replacement at steady growth rates and the linear response of the growth rates to pheH2 and p-fluorophenylalanine replacements suggest that growth is limited by one salient protein defect more than any other, possibly at a single critical peptide site. If multiple defects, either in several proteins or in several peptide sites in the same protein were needed to inhibit growth, they would be expected to interact cooperatively and produce a convex curve of growth response, perhaps as illustrated by ofluorophenylalanine (Fig. 2) . Even in this latter example pooperativity does not appear particularly striking. Moreover, the maximum peptide replacement by pheH2 of p-fluorophenylalanine when supplied alone is the same as the replacement limit arrived at by extrapolating partial replacements in steady-state growth to the zero growth rate. Thus, growth is limited finally by the same net analogue replacement regardless whether the analogue is randomly distributed in the target site or restricted to some molecules of it. If multiple peptide defects were needed to affect the protein target, the growth inhibition should be more apparent in the latter, nonrandomized condition where cooperative intramolecular interactions would be more probable. None of these arguments can be more than suggestive, but they provide a predictive framework for examining additional physiological effects of these analogues. Thus 
